Ningbo Jenscare Biotechnology Co., Ltd.

Zhejiang University

Ningbo Lumilan Advanced Materials Co., Ltd.

Zhi Kuan Chen

Shiwen Lv

Yibin Li

Jianan Li

Zhiyun Xu

Hua Sun

Wenming Zhu

Yanshan Huang

Kunshan Xie

Linfu Zhou

Deyuan Zheng

Fanglin Lu

A heart valve prosthesis anchored to an interventricular septum. The heart valve prosthesis includes a valve supporting frame and a fixing device. The valve supporting frame includes a valve stitching section and an artificial valve. The artificial valve is fixedly connected to the valve stitching section. The fixing device includes a fixing and supporting section and a fixing member. One end of the fixing and supporting section is connected to a proximal end of the valve stitching section, and another end of the fixing and supporting section is connected to the interventricular septum of a patient by the fixing member, to support the heart valve prosthesis and prevent the heart valve prosthesis from axially moving.

Heart valve prosthesis anchored to interventricular septum and conveying and releasing method thereof

The invention relates to a 9,10-dihydro-acridine derivative having a structure of Formula (I). The HOMO and LUMO levels of the 9,10-dihydro-acridine derivative are distributed on different electron donating and electron withdrawing groups, such that the HOMO and LUMO levels are separated, achieving a small &#x394;E. The 9,10-dihydro-acridine derivative can be used as a TADF material in an organic light-emitting device. The dihydro-acridinyl group in the electron donating group is linked to a dibenzoheterocyclic ring. Introducing modifying groups allows adjustment of triplet and singlet energy levels of the compound, enabling the TADF material to have a high luminescence efficiency in blue and deep blue regions. The invention also relates to an organic light-emitting device having at least one functional layer containing the 9,10-dihydro-acridine derivative. When the compound is used as a guest luminescent material in a light emitting layer, an OLED device of high blue light emitting efficiency is obtained.

9,10-dihydro-acridine derivative, and preparation method and use thereof

The present invention discloses a 9,10-dihydro-acridine derivative having a structure of Formula (I). The compound has a suitable HOMO energy level that matches that of an anode and light emitting layer when used as a material of a hole transport layer, thus reducing the potential barrier needed to overcome when holes are transported to the light emitting layer, and reducing the operating voltage of the device. Moreover, the 9,10-dihydro-acridine derivative has high triplet energy level and LUMO level, to avoid the returning of energy from the light emitting layer, retain the electrons in the light emitting layer, increase the probability of recombination of electrons and holes in the light emitting layer, and enhance the luminescence efficiency of the device. The compound of Formula (I) has high glass transition temperature, good film forming performance, and high thermal stability. The present invention further discloses an organic light-emitting device having at least one functional layer containing the 9,10-dihydro-acridine derivative. When the compound is used as a material of the hole transport layer, a light-emitting device of high luminescence efficiency and low driving voltage is obtained.

A prosthesis () for preventing a valve regurgitation, comprising a fixation unit (), a connection piece () and a closure assisting piece (); the fixation unit () comprises a fixation piece () and an anchor (); the connection piece () is flexible, and a distal section thereof is connected to a proximal section of the fixation piece (), and a proximal section thereof is connected to a distal section of the closure assisting piece (); the fixation piece () is fixed on the atrial wall or a valve ring of a patient via the anchor (); the deployed width of the fixation piece () is less than two-thirds of the circumference of a valve tissue annulus; the closure assisting piece () is located between autologous valve leaflets of the patient when in a free state; the maximum width of the closure assisting piece () is less than the maximum deployed width of a single autologous valve leaflet; and the proximal end of the anchor () is provided with an anti-disengagement end (). The position of the prosthesis () can be adjusted, and the prosthesis () is accurately positioned and firmly anchored, and does not readily adhere to tissue adjacent to the valve annulus of the patient.

Prosthesis for preventing valve regurgitation

An implant with anchoring device for heart valve disease comprises a cardiac valve prosthesis (), at least two sets of anchoring needles () and at least two sets of anchoring needle releasing devices (). Proximal end of the anchoring needles () are provided with anti-disengagement ends (). The anchoring needle releasing devices () are detachably connected to the cardiac valve prosthesis (). The anchoring needle releasing devices () comprise delivery tubes () and shafts (). Distal sections of the anchoring needle releasing devices () are in preset shapes. The shafts () can be pushed to force the anchoring needles () to move toward the distal ends of the delivery tubes (), so that the cardiac valve prosthesis () is fixed between autogenous tissue () and the anti-disengagement ends () to achieve accurate positioning and firm anchoring of the cardiac valve prosthesis ().

Implant with anchoring device for heart valve disease

The present invention relates to the field of biotechnology, and discloses a hepatitis B virus mutant, a mutant amplification kit and use thereof. The HBV mutant of the invention takes place mutation of the hepatitis B virus mutant in genome sequence No. 216 and/or 285, the mutation occurred at position 216 is that base T mutates to C, the mutation occurred at position 285 is that base G mutates to A. The two mutations are closely related to the inflammation aggravation of the hepatitis B. The invention further provides a HBV mutant amplification kit to detect the above mutation, the usage of the kit and its application, therefore offering help for the clinical early diagnosis and intervention of severe hepatitis B, and providing references for further studying the functional changes caused by HBV gene mutation.

Hepatitis B virus mutant, mutant amplification kit and use thereof

This present invention relates to compositions comprising biological active proteins fused with extended recombinant gelatin-like protein (GLK), nucleic acids encoding the compositions and vectors containing the same, approaches involved in the preparation of the compositions and their pharmaceutical application in the treatment or prevention of diseases.

Growing community of inventors

Ningbo, China

Zhi Kuan Chen